Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medplus Health Services informed that its subsidiary Optival Health Solutions received two drug license suspension orders from state drug control authorities. A store in Nuthankal Village, Telangana faced a 3-day suspension (order received May 1, 2025) under Rule 65 of the Drugs and Cosmetics Act, 1940, with a potential revenue loss of around Rs 0.55 lakh. A second store at Sajjan Rao Circle, Karnataka received a 2-day suspension with a potential revenue loss of about Rs 0.43 lakh. Both suspensions are short-term and pertain to individual retail outlets, not the broader business. The combined financial impact is under Rs 1 lakh, which is negligible for the company.
The financial impact is immaterial (under Rs 1 lakh combined) and limited to two individual stores over 2-3 days, so this is unlikely to affect the stock price or overall business. However, repeated license suspensions could attract regulatory scrutiny if they become a pattern.